Skip to contentS
Supernus Pharmaceuticals, Inc.
S
SUPNSupernus Pharmaceuticals, Inc. Q2 2015 · 10-Q
Revenue$35.68M$35.68M+20.2% vs Q2 2014 Net Income$2.44M$2.44M−23.9% vs Q2 2014 EPS Diluted$0.04$0.04−50.0% vs Q2 2014 Operating Income$3,844,000+2.3% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Supernus Pharmaceuticals, Inc. · CIK 1356576 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$14,081,000N/M Margins · derivedOperating margin10.8%−1.9 pt vs Q2 2014
Net margin6.8%−4.0 pt vs Q2 2014
ended Jun 30, 2015 · filed Aug 7, 2015 · 38 d after period end